Publicaciones en colaboración con investigadores/as de University Hospital of Geneva (13)

2024

  1. Correction to: MR beyond diagnostics at the ESMRMB annual meeting: MR theranostics and intervention (Magnetic Resonance Materials in Physics, Biology and Medicine, (2024), 37, 3, (323-328), 10.1007/s10334-024-01176-5)

    Magnetic Resonance Materials in Physics, Biology and Medicine

  2. MR beyond diagnostics at the ESMRMB annual meeting: MR theranostics and intervention

    Magnetic Resonance Materials in Physics, Biology and Medicine

  3. PEACE V-Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): Acute Toxicity of a Randomized Phase 2 Trial

    European urology oncology, Vol. 7, Núm. 3, pp. 462-468

2023

  1. Jorge clinical study: 10-year outcomes of risk-adapted radiotherapy defined by multiparametric MRI for prostate cancer

    World Journal of Urology, Vol. 41, Núm. 12, pp. 3829-3838

  2. Oligometastatic Hormone-Sensitive Prostate Cancer. Why Radiotherapy?

    Clinical Genitourinary Cancer, Vol. 21, Núm. 3, pp. e93-e103

  3. Role of Radiotherapy and Hormone Therapy in Patients with Node-Positive Locally Advanced Prostate Cancer

    Archivos espanoles de urologia, Vol. 76, Núm. 10, pp. 718-732

2022

  1. Oligorecurrent nodal prostate cancer: Radiotherapy quality assurance of the randomized PEACE V-STORM phase II trial

    Radiotherapy and Oncology, Vol. 172, pp. 1-9

  2. Recommendations for radiation therapy in oligometastatic prostate cancer: An ESTRO-ACROP Delphi consensus

    Radiotherapy and Oncology, Vol. 176, pp. 199-207

2021

  1. Extreme hypofractionation with sbrt in localized prostate cancer

    Current Oncology, Vol. 28, Núm. 4, pp. 2933-2949

  2. Is hypofractionation acceptable for prostate bed radiotherapy?

    Urologic Oncology: Seminars and Original Investigations, Vol. 39, Núm. 6, pp. 346-350

  3. Salvage local treatment for localized radio-recurrent prostate cancer: A narrative review and future perspectives

    Future Oncology, Vol. 17, Núm. 31, pp. 4207-4219

  4. The Multicenter, Randomized, Phase 2 PEACE V-STORM Trial: Defining the Best Salvage Treatment for Oligorecurrent Nodal Prostate Cancer Metastases

    European Urology Focus

2020

  1. PEACE V-Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): A study protocol for a randomized controlled phase II trial

    BMC Cancer, Vol. 20, Núm. 1